Patents by Inventor Richard A. Hotchkiss

Richard A. Hotchkiss has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220091133
    Abstract: A method of immune phenotyping (evaluating adaptive and innate immune status) a subject is disclosed that includes providing a biological sample comprising diluted whole blood or isolated peripheral blood mononuclear cells (PBMCs), quantitating T cell interferon-gamma (IFN-?) and monocyte TNF-? production using ELISpot in the biological sample comprising diluted whole blood, and determining that the subject has an immunosuppressive immunological endotype if T cell interferon-gamma (IFN-?) and/or monocyte TNF-? production are decreased or low compared to a healthy subject. The disclosed method may be used to evaluating drug efficacy by measuring immune function in a subject after administering a drug to the subject to determine changes in the immune function of the subject in response to the drug.
    Type: Application
    Filed: September 20, 2021
    Publication date: March 24, 2022
    Inventors: Richard Hotchkiss, Isaiah Turnbull, Monty Mazer, Kenneth Remy, Charles Caldwell, Lyle Moldawer, Scott Brakenridge
  • Patent number: 8168650
    Abstract: A series of N-substituted 9-azabicyclo[3.3.1]nonan-3?-yl phenylcarbamate analogs are disclosed, as well as methods of their preparation. Their affinities for sigma (?1 and ?2) receptors are described. Two new compounds, N-(9-(4-aminobutyl)-9-azabicyclo[3.3.1]nonan-3?-yl)-N?-(2-methoxy-5-methylphenyl)carbamate and N-(9-(6-aminohexyl)-9-azabicyclo[3.3.1]nonan-3?-yl)-N?-(2-methoxy-5-methylphenyl)carbamate, are shown to have a high affinity and selectivity for ?2 versus ?1 receptors. Among the disclosed compounds are biotinylated and fluorescent analogs. These compounds can serve as probes to the ?2 receptor. In addition, some disclosed compounds can induce apoptotic cell death by both caspase-dependent and caspase-independent mechanisms, and are effective for treatment of tumors. The compounds can be used as chemotherapeutics or chemosensitizers in the treatment of a wide variety of solid tumors.
    Type: Grant
    Filed: August 19, 2009
    Date of Patent: May 1, 2012
    Assignee: Washington University
    Inventors: Robert H. Mach, Richard Hotchkiss, William Hawkins, Rebecca Aft, Zhude Tu
  • Patent number: 8143222
    Abstract: Pharmaceutical compounds, pharmaceutical compositions and methods of treatment are disclosed, wherein a compound comprises a targeting moiety which, in free form, binds a cell receptor with a dissociation constant Kd of less than about 10?7 M, and a pharmaceutically active moiety, wherein the targeting moiety is other than an oligopeptide, a polypeptide, a peptidomimetic, a protein or a protein domain, and wherein the targeting moiety and the pharmaceutically active moiety are covalently attached. In some aspects, the targeting moiety binds a sigma-2 receptor with high affinity and high specificity, and the pharmaceutically active moiety is a pro-apoptotic peptide moiety. Methods of cancer treatment are disclosed comprising administering a disclosed pharmaceutical compound to a subject in need of thereof. The treatments selectively induce apoptosis in cancer cells. These methods can further comprise co-administration of radiation therapy and/or an additional chemotherapeutic agent.
    Type: Grant
    Filed: October 22, 2008
    Date of Patent: March 27, 2012
    Assignee: Washington University
    Inventors: Jonathan E. McDunn, William G. Hawkins, Robert H. Mach, Richard A. Hotchkiss
  • Patent number: 8107207
    Abstract: A potted electrical circuit is enclosed within a housing and has a first and second fiberglass layer that is laid upon a top surface of the potted electrical circuit. A lid of the housing seals the electrical circuit there within and an opening formed in a side wall allows circuitry wiring to extend there from out. The first fiberglass layer is a woven layer while the second fiberglass layer is a padding-like layer. Circuitry wiring pushes through the woven first fiberglass layer before extending out through the opening in the housing. The first fiberglass layer is tucked in and around the electrical circuit and adheres to the inside of the housing by attaching to the potting material while it hardens. In a preferred embodiment, the electrical circuit in combination with the insulation material is used within a transient voltage surge suppression device.
    Type: Grant
    Filed: August 8, 2008
    Date of Patent: January 31, 2012
    Assignee: Surge Suppression Incorporated
    Inventors: Ronald Hotchkiss, Richard Hotchkiss, Jr., Ricky Fussell, Andrea Haa
  • Patent number: 8107208
    Abstract: A potted electrical circuit is enclosed within a housing and has a first and second fiberglass layer that is laid upon a top surface of the potted electrical circuit. A lid of the housing seals the electrical circuit there within and an opening formed in a side wall allows circuitry wiring to extend there from out. The first fiberglass layer is a woven layer while the second fiberglass layer is a padding-like layer. Circuitry wiring pushes through the woven first fiberglass layer before extending out through the opening in the housing. The first fiberglass layer is tucked in and around the electrical circuit and adheres to the inside of the housing by attaching to the potting material while it hardens. In a preferred embodiment, the electrical circuit in combination with the insulation material is used within a transient voltage surge suppression device.
    Type: Grant
    Filed: August 21, 2008
    Date of Patent: January 31, 2012
    Assignee: Surge Suppression Incorporated
    Inventors: Ronald Hotchkiss, Richard Hotchkiss, Jr., Ricky Fussell, Andrea Haa
  • Patent number: 8038984
    Abstract: Methods and compositions for treating sepsis using cell membrane-permeant peptide conjugate covalent compounds having target cell specificity are provided.
    Type: Grant
    Filed: November 23, 2005
    Date of Patent: October 18, 2011
    Assignee: Washington University
    Inventors: Richard Hotchkiss, David Piwnica-Worms, Jonathan McDunn
  • Publication number: 20100121031
    Abstract: Methods and compositions for treating sepsis and diseases and conditions involving cellular apoptosis using cell membrane-permeant peptide conjugates of a cell membrane permeant peptide together with anti-apoptotic domains of the TCL1 protein are provided.
    Type: Application
    Filed: November 12, 2009
    Publication date: May 13, 2010
    Applicant: WASHINGTON UNIVERSITY
    Inventors: Richard Hotchkiss, David Piwnica-Worms, Jonathan McDunn, Ernesto Bernal-Mizrachi
  • Publication number: 20100048614
    Abstract: A series of N-substituted 9-azabicyclo[3.3.1]nonan-3?-yl phenylcarbamate analogs are disclosed, as well as methods of their preparation. Their affinities for sigma (?1 and ?2) receptors are described. Two new compounds, N-(9-(4-aminobutyl)-9-azabicyclo[3.3.1]nonan-3?-yl)-N?-(2-methoxy-5-methylphenyl)carbamate and N-(9-(6-aminohexyl)-9-azabicyclo[3.3.1]nonan-3?-yl)-N?-(2-methoxy-5-methylphenyl)carbamate, are shown to have a high affinity and selectivity for ?2 versus ?1 receptors. Among the disclosed compounds are biotinylated and fluorescent analogs. These compounds can serve as probes to the ?2 receptor. In addition, some disclosed compounds can induce apoptotic cell death by both caspase-dependent and caspase-independent mechanisms, and are effective for treatment of tumors. The compounds can be used as chemotherapeutics or chemosensitizers in the treatment of a wide variety of solid tumors.
    Type: Application
    Filed: August 19, 2009
    Publication date: February 25, 2010
    Applicant: WASHINGTON UNIVERSITY
    Inventors: Robert H. Mach, Richard Hotchkiss, William Hawkins, Rebecca Aft, Zhude Tu
  • Publication number: 20100033885
    Abstract: A potted electrical circuit is enclosed within a housing and has a first and second fiberglass layer that is laid upon a top surface of the potted electrical circuit. A lid of the housing seals the electrical circuit there within and an opening formed in a side wall allows circuitry wiring to extend there from out. The first fiberglass layer is a woven layer while the second fiberglass layer is a padding-like layer. Circuitry wiring pushes through the woven first fiberglass layer before extending out through the opening in the housing. The first fiberglass layer is tucked in and around the electrical circuit and adheres to the inside of the housing by attaching to the potting material while it hardens. In a preferred embodiment, the electrical circuit in combination with the insulation material is used within a transient voltage surge suppression device.
    Type: Application
    Filed: August 8, 2008
    Publication date: February 11, 2010
    Applicant: SURGE SUPPRESSION, INCORPORATED
    Inventors: Ronald Hotchkiss, Richard Hotchkiss, Jr., Ricky Fussell, Andrea Haa
  • Patent number: 7612085
    Abstract: A series of N-substituted 9-azabicyclo[3.3.1]nonan-3?-yl phenylcarbamate analogs are disclosed, as well as methods of their preparation. Their affinities for sigma (?1 and ?2) receptors are described. Two new compounds, N-(9-(4-aminobutyl)-9-azabicyclo[3.3.1]nonan-3?-yl)-N?-(2-methoxy-5-methylphenyl)carbamate and N-(9-(6-aminohexyl)-9-azabicyclo[3.3.1]nonan-3?-yl)-N?-(2-methoxy-5-methylphenyl)carbamate, are shown to have a high affinity and selectivity for ?2 versus ?1 receptors. Among the disclosed compounds are biotinylated and fluorescent analogs. These compounds can serve as probes to the ?2 receptor. In addition, some disclosed compounds can induce apoptotic cell death by both caspase-dependent and caspase-independent mechanisms, and are effective for treatment of tumors. The compounds can be used as chemotherapeutics or chemosensitizers in the treatment of a wide variety of solid tumors.
    Type: Grant
    Filed: July 11, 2007
    Date of Patent: November 3, 2009
    Assignee: Washington University
    Inventors: Robert H. Mach, Zhude Tu, Wenhua Chu, Suwanna Vangveravong, Richard Hotchkiss, William Hawkins, Rebecca Aft
  • Publication number: 20090176705
    Abstract: Pharmaceutical compounds, pharmaceutical compositions and methods of treatment are disclosed, wherein a compound comprises a targeting moiety which, in free form, binds a cell receptor with a dissociation constant Kd of less than about 10?7 M, and a pharmaceutically active moiety, wherein the targeting moiety is other than an oligopeptide, a polypeptide, a peptidomimetic, a protein or a protein domain, and wherein the targeting moiety and the pharmaceutically active moiety are covalently attached. In some aspects, the targeting moiety binds a sigma-2 receptor with high affinity and high specificity, and the pharmaceutically active moiety is a pro-apoptotic peptide moiety. Methods of cancer treatment are disclosed comprising administering a disclosed pharmaceutical compound to a subject in need of thereof. The treatments selectively induce apoptosis in cancer cells. These methods can further comprise co-administration of radiation therapy and/or an additional chemotherapeutic agent.
    Type: Application
    Filed: October 22, 2008
    Publication date: July 9, 2009
    Applicant: Washington University
    Inventors: Jonathan E. McDunn, William G. Hawkins, Robert H. Mach, Richard A. Hotchkiss
  • Publication number: 20090012025
    Abstract: Methods of treatment of sepsis are disclosed. These methods comprise administering to a subject a composition comprising at least one siRNA directed against at least one gene encoding a pro-apoptotic polypeptide. The pro-apoptotic polypeptide, in some aspects, can be other than Fas or caspase-8. In some embodiments, an siRNA can be directed against a pro-apoptotic component of the mitochondrial pathway, such as a pro-apoptotic bcl-2 protein. In some aspects, an siRNA can be directed against a BH3-only bcl-2 protein, while in other aspects, siRNAs can be directed against multi BH domain Bcl-2 family members such as bax and bak. In some embodiments, an siRNA can be directed against a death receptor pathway molecule such as FADD. In various configurations, a composition can also comprise a cationic lipid such as DOTAP, or nanoparticles comprising a cyclodextrin-containing polycation and a polymer such as a poly(ethylene glycol).
    Type: Application
    Filed: February 11, 2008
    Publication date: January 8, 2009
    Inventors: Richard Hotchkiss, Jonathan McDunn, David Piwnica-Worms, Steven Schwulst
  • Publication number: 20080304200
    Abstract: A potted electrical circuit is enclosed within a housing and has a first and second fiberglass layer that is laid upon a top surface of the potted electrical circuit. A lid of the housing seals the electrical circuit there within and an opening formed in a side wall allows circuitry wiring to extend there from out. The first fiberglass layer is a woven layer while the second fiberglass layer is a padding-like layer. Circuitry wiring pushes through the woven first fiberglass layer before extending out through the opening in the housing. The first fiberglass layer is tucked in and around the electrical circuit and adheres to the inside of the housing by attaching to the potting material while it hardens. In a preferred embodiment, the electrical circuit in combination with the insulation material is used within a transient voltage surge suppression device.
    Type: Application
    Filed: August 21, 2008
    Publication date: December 11, 2008
    Applicant: SURGE SUPPRESSION, INCORPORATED
    Inventors: Ronald Hotchkiss, Richard Hotchkiss, JR., Ricky Fussell, Andrea Haa
  • Patent number: 7417841
    Abstract: A circuit board is enclosed in a housing containing rows of metal oxide varistors. Multiple surge ferrule type fuses are soldered directly to circuit board holes between the rows of metal oxide varistors. A ring connector electrically connects pairs of fuses and an electrical conductor connects the ring connector to an electrical circuit to be protected.
    Type: Grant
    Filed: December 3, 2004
    Date of Patent: August 26, 2008
    Assignee: Surge Suppression, Inc.
    Inventors: Ronald Hotchkiss, Richard Hotchkiss
  • Publication number: 20080161343
    Abstract: A series of N-substituted 9-azabicyclo[3.3.1]nonan-3?-yl phenylcarbamate analogs are disclosed, as well as methods of their preparation. Their affinities for sigma (?1 and ?2) receptors are described. Two new compounds, N-(9-(4-aminobutyl)-9-azabicyclo[3.3.1]nonan-3?-yl)-N?-(2-methoxy-5-methylphenyl)carbamate and N-(9-(6-aminohexyl)-9-azabicyclo[3.3.1]nonan-3?-yl)-N?-(2-methoxy-5-methylphenyl)carbamate, are shown to have a high affinity and selectivity for ?2 versus ?1 receptors. Among the disclosed compounds are biotinylated and fluorescent analogs. These compounds can serve as probes to the ?2 receptor. In addition, some disclosed compounds can induce apoptotic cell death by both caspase-dependent and caspase-independent mechanisms, and are effective for treatment of tumors. The compounds can be used as chemotherapeutics or chemosensitizers in the treatment of a wide variety of solid tumors.
    Type: Application
    Filed: July 11, 2007
    Publication date: July 3, 2008
    Inventors: Robert H. Mach, Zhude Tu, Wenhua Chu, Suwanna Vangveravong, Richard Hotchkiss, William Hawkins, Rebecca Aft
  • Publication number: 20060263382
    Abstract: Methods and compositions for treating sepsis and diseases and conditions involving cellular apoptosis using cell membrane-permeant peptide conjugates of a cell membrane permeant peptide together with anti-apoptotic domains of the TCL1 protein are provided.
    Type: Application
    Filed: March 29, 2006
    Publication date: November 23, 2006
    Inventors: Richard Hotchkiss, David Piwnica-Worms, Jonathan McDunn, Ernesto Bernal-Mizrachi
  • Publication number: 20060166881
    Abstract: Methods and compositions for treating sepsis using cell membrane-permeant peptide conjugate covalent compounds having target cell specificity are provided.
    Type: Application
    Filed: November 23, 2005
    Publication date: July 27, 2006
    Inventors: Richard Hotchkiss, David Piwnica-Worms, Jonathan McDunn
  • Publication number: 20050122655
    Abstract: A circuit board is enclosed in a housing containing rows of metal oxide varistors. Multiple surge ferrule type fuses are soldered directly to circuit board holes between the rows of metal oxide varistors. A ring connector electrically connects pairs of fuses and an electrical conductor connects the ring connector to an electrical circuit to be protected.
    Type: Application
    Filed: December 3, 2004
    Publication date: June 9, 2005
    Inventors: Ronald Hotchkiss, Richard Hotchkiss